支持醫(yī)保知證決策的降糖新藥多維價(jià)值評(píng)估框架研究

打開文本圖片集

中圖分類號(hào)R977.1+5 文獻(xiàn)標(biāo)志碼A 文章編號(hào)1001-0408（2025）13-1563-05

DOI 10.6039/j.issn.1001-0408.2025.13.02

on the multi-dimensional value assessment framework new antidiabetic drugs to support evidence-inmed medical insurance decision-making

YAN Feifei1，CHEN Jingyu1，CHEN Jiaran1，PAN Chen1，WANG Guohua2，GENG Jinsongl（1. Inmatics， School of 226001，China;2.National Diseases， Hospital，Capital ，Beijing lOo053，China）

ABSTRACTOBJECTIVEToestablishamulti-dimensional valueassssentframework newantidiabeticdrugs basedon multi-criteriadecisionanalysistheorythusprovidingatheoreticalframeworkandmethodologyevidence-inmedmedical insurancedecision-making.METHODSFirstly，multi-dimensionalevidencewassearchedandobtainedtoprovidereliabledata theestablishmentoftheframework.Secondlyintersoftheobtainedevidence，thvalueassessmentframeworkwaspreliarily constructed.Itsstructure，maincorecriteria，andcontextualciteriaweredeterminedtrough focusgroupdiscussion.inally，the crieriaandsub-riteriaoftheframeworkandtheirweightswerefurtherdetermined，reasonsinclusionofsub-riteriaandthe reasonablenessofrating scores were evaluated，and methodsof assessment wereoptimized through expert consultation.REULTS Themulti-dimensionalvalueasessentframeworknewantidiabeticdrugswascomposedofcorecriteriaandcontextualized criteriawhichcouldbeusedquantitativeandqualitativevalueassessmentofnewdrugs，respectively.Thecorecriteria consistedoffivedimensions，withaffrdability（6.31）havingthehighestweightingscore，followedbycomparativeefectivenes （6.20），comparativesafety（6.01），cost-efectiveness（5.89），andqualityofevidence（5.46）.Afterthenormalizationof weight withinsub-criteria，the budgetimpactonmedicalinsurancehadthehigheststandardized weight，folowedbythecontrolof glycatedemoglobinandpatientadability.Thecontextualcriteriaincludedtwodimensions，i.e.，innovationandequity. CONCLUSIONSTheassessmentframework integratesevidence，stakeholders’values，anddecisioncontexts toenableamulidimensional and evidence-based assessment of the value of new antidiabetic drugs.

KEYWORDsnewantidiabeticdrugs；evidence-inmed decision-making；medical insurance；valueasessment framework; multi-criteria decision analysis

糖尿病是嚴(yán)重影響人民身體健康和生活質(zhì)量的慢性非傳染性疾病。（剩余9282字）